Abstract P2093: Chronic Kidney Disease Severity and Incident Cognitive Impairment in Patients with Chronic Kidney Disease: Findings from the Chronic Renal Insufficiency Cohort

Z Zhijie Huang K Kristine Yaffe Y Yang Pan (National Synchrotron Radiation Laboratory) C Changwei Li M mark unruh (University of New Mexico, Albuquerque, New Mexico, United States) M Matthew Weir (Univ. Maryland School of Medicine, Baltimore, Maryland, United States) B Bernard Jaar P Panduranga Rao (University of Michigan, Ann Arbor, Michigan, United States) M Mahboob Rahman V Vallabh Shah (University of New Mexico, Albuquerque, New Mexico, United States) J Jonathan Taliercio (Cleveland Clinic, Cleveland, Ohio, United States) A Amanda Anderson K Katherine Mills (TULANE UNIVERSITY, New Orleans, Louisiana, United States) L Lydia Bazzano (Tulane University, New Orleans, Louisiana, United States) J Jing Chen J Jiang He A Ana Ricardo (University of Illinois Chicago, Chicago, Illinois, United States) J James Lash (University of Illinois Chicago, Chicago, Illinois, United States) M Manjula Tamura (Stanford University, Stanford, California, United States) T Tanika Kelly (University of Illinois Chicago, Chicago, Illinois, United States)

Abstract

Background: Patients with chronic kidney disease (CKD) face a disproportionate burden of dementia compared to the general population. However, prospective associations between kidney function and cognitive impairment remain inconsistent and have not been exclusively evaluated in CKD. Methods: This analysis included 4,261 CKD patients from the Chronic Renal Insufficiency Cohort (CRIC). CKD severity was defined using standard estimated glomerular filtration rate (eGFR) and urinary protein to creatinine ratio (UPCR) thresholds. Global cognition and domains of verbal memory, attention/processing speed, and executive function were assessed longitudinally using the modified mini-mental status examination (3MS), Buschke Selective Reminding test, Trail Making Test A (TMTA), and Trail Making Test B (TMTB), respectively. For each test, impairment was defined as a score at least one standard deviation (SD) worse than the cohort mean at baseline. Cox proportional hazard models assessed associations between baseline CKD severity and time-to-cognitive impairment, adjusting for demographic and lifestyle risk factors, clinical measures, medications, and baseline cognition. Restricted cubic splines evaluated non-linear relations of both eGFR and UPCR with cognitive impairment. Results: Among CRIC participants with a mean age 59.6 years and median follow-up of 14.7 years, we observed significant, dose-response associations between increasing CKD severity, based on both eGFR and UPCR, and incident global cognitive impairment. Compared to those with stage G2 CKD (eGFR=60-89), patients with stage G4/G5 CKD (eGFR<30) had a 36% increased risk of cognitive impairment (HR=1.36; 95% CI=1.00, 1.86; P linear =0.03). Similarly, patients with UPCR>500 mg/g had a 26% increased risk compared to those with UPCR<150 mg/g (HR=1.26; 95% CI=0.99, 1.59; P linear =0.04). Increased CKD severity based on eGFR was significantly associated with attention impairment (G4/G5 vs. G2 HR=1.49; 95% CI=1.03, 2.14; P linear =0.04). Spline analyses revealed linear relationships between declining eGFR and impairment in global cognition (P=0.007) and attention (P=0.005), and between increasing UPCR and impairment in attention (P=0.015) and executive function (P=0.036; Figure ). No evidence of non-linear relationships were observed. Conclusion: More severe CKD, reflected by lower eGFR and higher UPCR, was prospectively associated with impairment in global cognition and specific cognitive domains.

Article Details

Journal Circulation
Volume / Issue Vol. 151, Issue Suppl_1
Published March 11, 2025
ISSN 0009-7322
Publisher Lippincott Williams & Wilkins

Journal Info

Circulation

Lippincott Williams & Wilkins

ISSN: 0009-7322 Health Sciences

Authors (20)

Z

Zhijie Huang

K

Kristine Yaffe

Y

Yang Pan

National Synchrotron Radiation Laboratory

C

Changwei Li

M

mark unruh

University of New Mexico, Albuquerque, New Mexico, United States

M

Matthew Weir

Univ. Maryland School of Medicine, Baltimore, Maryland, United States

B

Bernard Jaar

P

Panduranga Rao

University of Michigan, Ann Arbor, Michigan, United States

M

Mahboob Rahman

V

Vallabh Shah

University of New Mexico, Albuquerque, New Mexico, United States

J

Jonathan Taliercio

Cleveland Clinic, Cleveland, Ohio, United States

A

Amanda Anderson

K

Katherine Mills

TULANE UNIVERSITY, New Orleans, Louisiana, United States

L

Lydia Bazzano

Tulane University, New Orleans, Louisiana, United States

J

Jing Chen

J

Jiang He

A

Ana Ricardo

University of Illinois Chicago, Chicago, Illinois, United States

J

James Lash

University of Illinois Chicago, Chicago, Illinois, United States

M

Manjula Tamura

Stanford University, Stanford, California, United States

T

Tanika Kelly

University of Illinois Chicago, Chicago, Illinois, United States